Inhibition of neutral proteases from polymorphonuclear (PMN) neutrophils by salicylazosulfapyridine (SASP).
Cytochemical methods were used to demonstrate the inhibitory effect of salicylazosulfapyridine (SASP) on the activity of neutral proteases produced by neutrophilic granulocytes (PMN proteases). The SASP metabolites (5-aminosalicylic acid and sulfapyridine), produced by splitting of SASP by bacteria in the colon, did not inhibit the activity of PMN proteases. Paradoxically, sulfapyridine intensified PMN protease activity. A similar effect however could not be demonstrated for 5-aminosalicylic acid.
D000328:Adult; D000636:Aminosalicylic Acids / Q000494:pharmacology; D006801:Humans; D009504:Neutrophils / Q000187:drug effects / Q000201:enzymology*; D011480:Protease Inhibitors; D013427:Sulfapyridine / Q000494:pharmacology; D012460:Sulfasalazine / Q000494:pharmacology*
D000636:Aminosalicylic Acids; D011480:Protease Inhibitors; D012460:Sulfasalazine; D013427:Sulfapyridine